Kinomica key facts
- Developer of a phosphoproteomic diagnostic platform designed to enhance tailored treatment decisions involving anticancer drug therapies.
- Kinomica’s last known valuation is $16.6M.
- It has raised $13.1M; the latest was Later Stage VC ($5.6M) in Jul 2024.
- Notable investors include Innovate UK, Mercia Ventures, BGF (Financial Services), Puffin Point, Alderley Park — 11 tracked in total.
- Status: Privately Held (backing).
Who backs Kinomica
11+- ·The complete investor list: 11 names
- ·Watch Kinomica: the Monday email on marks, rounds and moves
Kinomica funding rounds
No funding rounds for Kinomica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kinomica valuation
Kinomica's last known valuation is $16.6 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Kinomica investors
11 investors are on record for Kinomica, including Innovate UK, Mercia Ventures, BGF (Financial Services) and Puffin Point.
About Kinomica
Developer of a phosphoproteomic diagnostic platform designed to enhance tailored treatment decisions involving anticancer drug therapies. The company's platform provides a suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can access direct activity measurements of multiple endogenous kinases and comprehensive cell signal network coverage, enabling patients to determine disease mechanisms, while upscaling drug targeting and biomarker identification.
- Sector
- Healthcare
- HQ
- Macclesfield, United Kingdom
- Founded
- 2016
- Employees
- 30
- Website
- kinomica.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kinomica’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.